Consistently, the ablation of p50, as well as pharmacological inhibition of EP2 by AH6809, has reprogrammed M-MDSC towards a NOS2low/TNFαhigh phenotype, restoring the in vivo anti-tumor activity of IFNγ [77]. This evidence concerns the gene CD40 and neoplasm.